Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 368-381

  Sobrero, A F ^a   Aschele, C ^a   Bertino, J R ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; RALTITREXED;

ANTINEOPLASTIC ACTIVITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0031015454     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.368     Document Type: Review

References (163)

1. Pinedo HM, Peters GJ: 5-Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664, 1988
2. Kemeny N: Chemotherapy for colorectal carcinoma: One small step forward, one step backward. J Clin Oncol 13:1287-1290, 1995
3. Cunningham D, Zalcberg J, Francois E, et al: Tomudex (ZD1694) a new thymidylate synthase inhibitor with good antitumor activity in advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 13:199, 1994 (abstr 584)
4. Jackman AL, Farrugia DC, Gibson W, et al: ZD 1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 31A:1277-1282, 1995
5. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
6. Pitot HC, Wender D, O'Connell MJ, et al: A phase II trial of CPT-11 (Irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 13:197, 1994 (abstr 573)
7. Armand JP, Ducreux M, Mahjoubyi M, et al: CPT-11 (Irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A:1283-1287, 1995
8. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670, 1995
9. Peters GJ, Van der Wilt CL, Van Groeningen CJ, et al: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil. J Clin Oncol 12:2035-2042, 1994
10. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647, 1994
11. Starzynska T, Bromley M, Ghosh A, et al: Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66:558-562, 1992
12. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
13. Grem JL: Future challenges for the systemic therapy of metastatic colorectal cancer, in American Society of Clinical Oncology Educational Book. Thirty-First Annual Meeting of the American Society of Clinical Oncology. Los Angeles, CA, 1995, pp 55-58
14. Goh HS, Yao J, Smith DR: p53 point mutation and survival in colorectal cancer patients. Cancer Res 55:5217-5221, 1995
15. Milano G, Etienne MC, Renee N, et al: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291-1295, 1994
16. El Tahtawy A, Wolf W: In vivo measurements of intra tumoral metabolism, modulation and pharmacokinetics of 5-fluorouracil using 19-F nuclear magnetic resonance spectroscopy. Cancer Res 51:5806-5812, 1991
17. Presant CA, Wolf W, Albright MJ: Human tumor fluorouracil trapping: Clinical correlations of in vivo 19-F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol 8:1868-1873, 1990
18. Aschele C, Sobrero A, Faderan MA, et al: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855-1864, 1992
19. Sobrero A, Aschele C, Guglielmi A, et al: Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 85:1937-1944, 1993
20. Mori A, Bertoglio S, Guglielmi A, et al: Activity of continuous infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 33:179-180, 1993
21. Sobrero AF, Aschele C, Guglielmi A, et al: Schedule-selective biochemical modulation of 5-fluorouracil: A phase II study in advanced colorectal cancer. Clin Cancer Res 1:955-960, 1995
22. Guglielmi A, Aschele C, Mori A, et al: In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells. Clin Cancer Res 1:334-341, 1995
23. Sobrero A, Aschele C, Frassineti GL, et al: High activity of alternating bolus 5-fluorouracil modulated by methotrexate and natural beta interferon and continuous infusion FUra modulated by 6-S-leucovorin in advanced colorectal cancer. Proc Am Soc Clin Oncol 14:211, 1995 (abstr 520)
24. Gorlick R, Rode W, Miles JS, et al: Purification and cloning of uridine monophosphate kinase (UMPK) and its role in 5-fluorouracil resistance. Proc Am Soc Clin Oncol 15:189, 1996 (abstr 403)
25. Poon MA, O'Connel MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1408, 1989
26. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
27. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
28. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
29. Ehrlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988
30. Cricca A, Martoni A, Guaraldi M, et al: Randomized clinical trial of 5-FU + folinic acid vs 5-FU in advanced gastrointestinal cancers. Proc Eur Soc Med Oncol 13:107, 1988 (abstr 427)
31. Petrelli N, Douglass OH Jr, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989
32. Laufman LR, Bukowski RM, Collier MA, et al: A randomized double blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer J Clin Oncol 11:1888-1893, 1993
33. Budd GT, Fleming TR, Bukowsky RM, et al: 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: A randomized comparison. A Southwest Oncology Group study. J Clin Oncol 5:272-277, 1987
34. Valone FH, Friedman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil, leucovorin. A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989
35. Labianca R, Pancera G, Aitini C, et al: Folinic acid + 5-fluorouracil versus equidose 5-FU in advanced colorectal cancer. Phase III study of GISCAD (Italian Group for the study of Digestive Tract Cancer). Ann Oncol 2:673-679, 1991
36. Nobile MT, Rosso R, Sertoli MR, et al: Randomized comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 28A:1823-1827, 1992
37. Di Costanzo F, Bartolucci R, Calabresi F, et al: Fluorouracil alone versus high dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 3:371-376, 1992
38. Jones D, Winn R, Brown BW, et al: Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl lomustine for patients with advanced colorectal cancer. Cancer 76:1709-1714, 1995
39. Leichman CG, Fleming TL, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1312, 1995
40. De Gramont A, Bosset JF, Milan C, et al: A prospectively randomized trial comparing 5FU bolus with low dose folinic acid (FUFOLld) and 5FU bolus plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer. Proc Am Soc Clin Oncol 14:194, 1995 (abstr 455)
41. Corfu-A Study Group: Phase III randomized study of two fluorouracil combinations with either interferon alpha 2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921-928, 1995
42. Zalcberq J, Cunningham D, Rath U, et al: Tomudex (ZD 1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than fluorouracil and leucovorin for advanced colorectal cancer: first results of a phase III study. Eur J Cancer 31A:146, 1995 (suppl 5, abstr 701)
43. Dallavalle G, Labianca R, Cascinu S, et al: High dose vs low dose 1-leucovorin as a modulator of 5-days 5-fluorouracil in advanced colorectal cancer: A GISCAD phase III study. Tumori 81:9, 1995 (abstr 3)
44. Heys SD, Eremin O, Ruggeri EM, et al: A phase III study of recombinant interleukin 2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal cancer. Eur J Cancer 31:19-25, 1995
45. Petrelli NJ: It is time to stratify with prognostic factors for hepatic metastases. J Clin Oncol 13:2471-2472, 1995
46. Fuchs CS, Mayer RJ: Colorectal cancer chemotherapy, in Rustgy AK (ed): Gastrointestinal Cancers: Biology, Diagnosis and Therapy. Philadelphia, PA, Lippincott-Raven, 1995, pp 423-442
47. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 7:1447-1456, 1989
48. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 332:352-358, 1990
49. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
50. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al: Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177-1183, 1994
51. O'Connel MJ, Mailliard J, Macdonald JS, et al: An intergroup trial of intensive course 5-FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer. Proc Am Soc Clin Oncol 12:190, 1993 (abstr 552)
52. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939-944, 1995
53. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
54. Haller DG: An overview of adjuvant chemotherapy for colorectal cancer. Eur J Cancer 31A:1255-1263, 1991
55. Labranca R, Moursoni S, Pancera G, et al: Efficacy of adjuvant fluorouracil and folonic acid in colon cancer. Lancet 345:939-944, 1995
56. Wolmark N, Rockette H, Mamounas EP, et al: The relative efficacy of 5FU and leucovorin, 5FU and levamisole in patients with Dukes B and C carcinoma of the colon: First report of NSABP C-04. Proc Am Soc Clin Oncol 15:205, 1996 (abstr)
57. Advanced Colorectal Cancer Meta-Analysis Project: Metaanalysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12:960-969, 1994
58. Mayer RJ: Chemotherapy for metastatic colorectal cancer. Cancer 70:1414-1420, 1992
59. Marsh JC, Bertino JR, Davis CA, et al: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9:371-380, 1991
60. Ahlgren JD: Colorectal cancer: Chemotherapy, in Ahlgren JD, McDonald JS (eds): Gastrointestinal Oncology. Philadelphia, PA, Lippincott, 1992, pp 339-357
61. Machiavelli M, Leone BA, Romero A, et al: Advanced colorectal carcinoma: A prospective randomized trial of sequential methotrexate, 5-fluorouracil and leucovorin versus 5-fluorouracil alone. Am J Clin Oncol 14:211-217, 1991
62. Herrmann R, Knuth A, Kleeberg U, et al: Sequential methotrexate and 5-fluorouracil vs 5-fluorouracil alone in metastatic colorectal cancer. Ann Oncol 3:539-543, 1992
63. Delfino C, Caccia G, Maniago O: 5-Fluorouracil alone vs methotrexate plus leucovorin plus fluorouracil in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 11:177, 1992 (abstr 521)
64. Abad A, Garcia P, Gravalos C, et al: Sequential methotrexate, 5-fluorouracil (5-FU) and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. Cancer 75:1238-1244, 1995
65. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
66. Blijham GH, Stellestags J, Sahmoud T, et al: The modulation of high dose 5-fluorouracil with low dose methotrexate in metastatic colorectal cancer: A phase III study of the EORTC GI Cancer Cooperative Group. Proc Am Soc Clin Oncol 12:199, 1993 (abstr 586)
67. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Superiority of sequential methotrexate fluorouracil and leucovorin vs fluorouracil alone in advanced symptomatic colorectal carcinoma. A randomized trial. J Clin Oncol 7:1437-1446, 1989
68. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 10:904-911, 1992
69. Glimelius B: Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 4:235-240, 1993
70. Raderer M, Scheithauer W: Treatment of advanced colorectal cancer with 5-fluorouracil and interferon alpha: An overview of clinical trials. Eur J Cancer 31:1002-1008, 1995
71. Leichman L, Fabian C, O'Bryan R, et al: Evaluation of 5-FU: A phase II in metastatic adenocarcinoma of the large bowel. Proc Am Soc Clin Oncol 2:120, 1983 (abstr 469)
72. Mayer RJ, McIntyre JM, Steele GD: High dose bolus 5-fluorouracil (FU) for metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 2:127, 1983 (abstr 498)
73. Seifert P, Baker LH, Reed ML, et al: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123-128, 1975
74. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989
75. Weinerman B, Shah A, Fields A, et al: A randomized trial of continuous systemic infusion vs bolus therapy with 5-fluorouracil in metastatic measurable colorectal cancer. Proc Am Soc Clin Oncol 9:103, 1990 (abstr 399)
76. Doroshow JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990
77. Rougier P, Paillot B, Laplanche A, et al: End results of a multicentric randomized trial comparing 5-FU in continuous systemic infusion to bolus administration in measurable metastatic colorectal cancer. Proc Am Soc Clin Oncol 11:163, 1992 (abstr 465)
78. Bajetta E, Colleoni M, Rosso R, et al: Prospective randomized trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. Eur J Cancer 29A:1658-1663, 1993
79. Ansfield F, Klotz J, Nealon T, et al: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 39:34-40, 1977
80. Hansen L, Ryan L, Anderson T, et al: A phase III trial of bolus 5-FU versus protracted infusion 5-FU ± cisplatin in metastatic colorectal cancer. An ECOG study. Proc Am Soc Clin Oncol 11: 171, 1992 (abstr 499)
81. Richards F, Case LD, White DR, et al: Combination chemotherapy (5-fluorouracil, methyl CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association. J Clin Oncol 4:565-570, 1986
82. Horton J, Olson KB, Sullivan J, et al: 5-Fluorouracil in cancer: An improved regimen. Ann Intern Med 73:897-905, 1970
83. Hryniuk WM, Figueredo A, Goodyear M: Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14:3-11, 1987
84. Wils JA: High dose fluorouracil: A new prospective in the treatment of colorectal cancer. Semin Oncol 19:126-130, 1992
85. Shah A, Mc Donald W, Goldie J, et al: 5-FU infusion in advanced colorectal cancer: A comparison of three dose schedules. Cancer Treat Rep 69:739-742, 1985
86. Lokich JJ, Ahlgren JD, Cantrell J, et al: A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. Cancer 67:14-19, 1991
87. Hill M, Norman A, Cunningham D, et al: Impact of protracted venous infusion fluorouracil with or without interferon alpha-2b on tumor response, survival and quality of life in advanced colorectal cancer. J Clin Oncol 13:2317-2323, 1995
88. Kemeny N, Israel K, Niedzwiecki, D et al: Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 8:313-318, 1990
89. Moertel CG, Shutt AJ, Reitemeier RJ, et al: A comparison of 5-fluorouracil administered by slow infusion and rapid injection. Cancer Res 32:2717-2719, 1972
90. Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107:459-465, 1987
91. Wooley P, Ayoob M, Smith FP: A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (Allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil. J Clin Oncol 3:103-109, 1985
92. Trump DL, Egorin MJ, Forrest A: Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 11:2027-2035, 1991
93. Ardalan B, Singh G, Silberman H: A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacelyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancer. J Clin Oncol 6:1053-1058, 1988
94. Glimelius B, Hoffman K, Graf W, et al: Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 73:556-562, 1994
95. Machover D, Grison X, Goldshmidt E, et al: Fluorouracil combined with the pure (6-S) isomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: A phase I-II study. J Natl Cancer Inst 84:321-327, 1992
96. Petrelli N, Creaven PJ, Rustum YM, et al: Phase I trial of 5-fluorouracil with a pharmacokinetically determined dose of leucovorin in colorectal carcinoma. Proc Am Soc Clin Oncol 9:144, 1990 (abstr 561)
97. Kohne CH, Schmoll HJ, Hiddemann W, et al: Phase II evaluation of 5-fluorouracil plus folinic acid and alpha 2b interferon in metastatic colorectal cancer. Oncology (in press)
98. Valeriote FA, Edelstein M: Cellular basis for infusional chemotherapy, in Lokich JJ (ed): Cancer Chemotherapy by Infusion (ed 2). Chicago, IL, Precept, 1990, pp 42-50
99. Mitchell RB, Ratain MJ, Vogelzang NJ: Experimental rationale for continuous infusion chemotherapy, in Lokich JJ (ed): Cancer Chemotherapy by Infusion (ed 2). Chicago, IL, Precept, 1990, pp 3-34
100. Fraile RJ, Baker LH, Buroker TR, et al: Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40:2223-2228, 1980
101. Grem JL: Fluorinated pyrimidines, in Chabner BA, Collins JM (eds): Cancer Chemotherapy. Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 180-224
102. Nord LD, Stolfi RL, Martin DS: Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue: Correlation of antitumor activity with dosage and FUra incorporation into RNA. Biochem Pharmacol 43:2543-2549, 1992
103. Nord LD, Martin DS: Loss of murine tumor thymidine kinase activity in vivo following 5-fluorouracil (FUra) treatment by incorporation of FUra into RNA. Biochem Pharmacol 42:2369-2375, 1991
104. Evans RM, Laskin JD, Hakala MT: Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res 40:4113-4122, 1980
105. Wilkinson D, Crumly J: The mechanism of 5-fluorouridine toxicity in Novikoff hepatoma cells. Cancer Res 36:4032-4038, 1976
106. Maybaum J, Ullman B, Mandel HG, et al: Regulation of RNA- and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res 40:4209-4215, 1980
107. Radparvar S, Houghton PJ, Germain G, et al: Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency. Biochem Pharmacol 39:1759-1765, 1990
108. Piper AA, Fox RM: Biochemical basis for the differential sensitivity of human T- and B-lymphocyte lines to 5-fluorouracil. Cancer Res 42:3753-3760, 1982
109. Washtien WL: Comparison of 5-fluorouracil metabolism in two human gastrointestinal tumor cell lines. Cancer Res 44:909-914, 1984
110. Santelli G, Valeriote F: Schedule-dependent cytotoxicity of 5-fluorouracil in mice. J Natl Cancer Inst 76:159-164, 1986
111. Calabro-Jones PM, Byfield JE, Ward JF, et al: Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 42:4413-4420, 1982
112. Ardalan B, Cooney DA, Jayaram HN, et al: Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil. Cancer Res 40:1431-1437, 1980
113. Pizzorno G, Handschumacher RE: Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem Pharmacol 49:559-565, 1995
114. Izzo J, Zarba JJ, Rougier P, et al: Low dose 5-FU continuous infusion in advanced colorectal cancer: Clinical evidence for reversal of acquired/intrinsic resistance to 5-FU or 5-FU folinic acid. Proc Am Assoc Cancer Res 33:217, 1992 (abstr 1298)
115. Hartmann H, Kennsinger A, Lemon H: Five days continuous infusion 5-fluorouracil for advanced colorectal gastric and pancreatic adenocarcinomas. J Surg Oncol 11:227-238, 1979
116. Poplin EA, Kraut M, Baker L, et al: A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma. Cancer 67:367-371, 1991
117. Hill M, Norman A, Cunningham D, et al: Royal Marsden phase III trial of fluorouracil with or without interferon alpha 2-B in advanced colorectal cancer. J Clin Oncol 13:1297-1302, 1995
118. Wadler S, Schwartz EL, Goldman L, et al: Fluorouracil and recombinant alfa 2-a interferon: An active regimen against advanced colorectal cancer. J Clin Oncol 7:1769-1775, 1989
119. van der Wilt CL, Peters GJ: New targets for pyrimidine antimetabolites in the treatment of solid tumors. Pharm World Sci 16:84-103, 1994
120. Nadal JC, Van Groeningen CJ, Pinedo HM, et al: In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother 42:387-393, 1988
121. Houghton JA, Williams LG, Loftin SK, et al: Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 30:423-432, 1992
122. Rustum YM: Selective modulation of 5-fluorouracil action in patients with colorectal carcinoma. Chemioterapia 4:377-382, 1985
123. Cao S, Duranni F, Rustum YM: Antitumor activity of fluorouracil/6-(RS)-leucovorin (FUra/LV) in rats bearing colon carcinoma: Role of dose and schedule. Proc Am Assoc Cancer Res 33:422, 1992 (abstr 2518)
124. Peters GJ, Codacci-Pisanelli G, van der Wilt CL, et al: Comparison of continuous infusions and bolus injections of 5-fluorouracil with or without leucovorin: Implications for inhibition of thymidylate synthase, in Rustum YM (ed): Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation. New York, NY, Plenum, 1993, pp 9-20
125. Beck A, Etienne MC, Chéradame S, et al: Wide range for optimal concentration of folinic acid in fluorouracil modulation -Experimental data on human tumour cell lines. Eur J Cancer 30A:1522-1526, 1994
126. Jolivet J: Role of leucovorin dosing and administration schedule. Eur J Cancer 31A:1311-1315, 1995
127. Moran RG, Scanlon KL: Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 51:4618-4623, 1991
128. Waxman S, Bruckner H: The enhancement of 5-fluorouracil antimetabolic activity by leucovorin, menadione and a-tocopherol. Eur J Cancer Clin Oncol 18:685-692, 1982
129. Cadman E, Heimer R, Davis L: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 205:1135-1137, 1979
130. Fernandes DJ, Bertino JR: 5-Fluorouracil-methotrexate synergy. Enhancement of 5-fluorodeoxyuridine binding to thymidylate synthetase by dihydropteroylpolyglutamates. Proc Natl Acad Sci USA 77:5663-5667, 1980
131. Benz C, Schoenberg M, Choti M, et al: Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. J Clin Invest 66:1162-1165, 1980
132. Cadman E, Heimer R, Benz C: The influence of methotrexate pre-treatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 256:1695-1704, 1981
133. Benz C, Cadman E: Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolites in human colorectal adenocarcinoma. HCT-8. Cancer Res 41:994-999, 1981
134. Kufe DW, Egan EM: Enhancement of 5-fluorouracil incorporation into human lymphoblast ribonucleic acid. Biochem Pharmacol 30:129-133, 1981
135. Benz C, Tillis T, Tattelman E, et al: Optimal scheduling of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res 42:2081-2086, 1982
136. Mini E, Moroson BA, Blair OC, et al: Time, dose and sequence relationships for methotrexate, fluorouracil and their combinations for optimal cell kill in the human T-lymphoid cell line CCRF-CEM. Chemioterapia 2:452-453, 1983 (suppl 5)
137. Mini E, Bertino JR: Time and dose relationships for methotrexate (MTX), fluorouracil (FUra) and combinations of these drugs for maximum cell kill in human CCRF-CEM cells. Proc Am Assoc Cancer Res 23:181, 1982 (abstr 712)
138. Major PP, Egan EM, Sargent L, et al: Modulation of 5-fluorouracil metabolism in human MCF-7 breast carcinoma cells. Cancer Chemother Pharmacol 8:87-91, 1982
139. Sobrero AF, Bertino JR: Sequence-dependent synergism between dichloromethotrexate and 5-fluorouracil in a human colon carcinoma cell line. Cancer Res 43:4011-4013, 1983
140. Tattersall MHN, Jackson RC, Connors TA, et al: Combination chemotherapy: The interaction of methotrexate and 5-fluorouracil. Eur J Cancer 9:733-739, 1973
141. Donehower RC, Allegra JC, Lippman ME, et al: Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture. Eur J Cancer 16:655-661, 1980
142. van der Wilt CL, Braakhuis BJM, Pinedo HM, et al: Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: Potentiating or reversing effect? Int J Cancer 61:672-678, 1995
143. Sobrero AF, Romanini A, Russello, et al: Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: Implications for the mechanism of this interaction. Eur J Cancer Clin Oncol 25:977-982, 1989
144. Mortimer J, Higano C: Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer. Cancer Invest 6:129-132, 1988
145. Loeffler TM, Weber FW, Hausamen TU: Protracted continuous infusion 5-fluorouracil with intermittent high dose leucovorin in advanced and metastatic colorectal cancer: A pilot study, in Pinedo HM, Rustum YM (eds): Leucovorin Modulation of Fluoropyrimidines: A New Frontier in Cancer Chemotherapy. London, United Kingdom, Royal Society of Medicine Services, 1989, pp 65-69
146. Ardalan B, Chua L, Tian E, et al: A phase II study of weekly 24 hour infusion with high dose 5-fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9:625-630, 1991
147. Tempero M, Berg A, Block M, et al: A phase II trial of protracted therapy with 5-fluorouracil and leucovorin in metastatic colorectal cancer. Proc Am Soc Clin Oncol 11:189, 1992 (abstr 571)
148. Leichman CG, Leichman L, Spears CP, et al: Prolonged infusion of fluorouracil with weekly bolus leucovorin: A phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 85:41-44, 1993
149. Lokich JJ, Phillips D, Green R, et al: 5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion, a phase I study. Cancer 56:2395-2398, 1985
150. Zaniboni A, Labianca R, Martignoni G: Sequential methotrexate and 5-fluorouracil as second line chemotherapy for advanced colorectal cancer pretreated with 5-fluorouracil and leucovorin: A GISCAD study. J Chemother 8:82-85, 1996
151. DeGramont A, Krulik M, Cady J, et al: High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 24:1499-1503, 1988
152. Johnson PW, Thompson PI, Seymour MT, et al: A less toxic regimen of 5-fluorouracil and high dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 64:603-605, 1991
153. Louvet C, De Gramont A, Bennamoun M: High dose folinic acid, 5-fluorouracil bolus and continuous infusion in metastatic colorectal cancer: A 3-day/3-week schedule. Eur J Cancer 28:611-612, 1992
154. Jodrell DI, Murray LS, Reed NS, et al: Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: Are suboptimal dosages being used in the UK? Br J Cancer 70:749-752, 1994
155. Seymour MT, Slevin M, Cunningham D, et al: A randomized trial to assess the addition of interferon alpha 2a to 5-fluorouracil and leucovorin in advanced colorectal cancer. Br J Cancer 69:24, 1994
156. Hanna CL, Mc Kinna FE, Williams LB, et al: High dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Br J Cancer 72:774-776, 1995
157. Romanini A, Li WW, Colofiore JR, et al: Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracu, in CCRF-CEM cells. J Natl Cancer Inst 84:1033-1038, 1992
158. Conti JA, Kemeny N, Seiter K, et al: Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 12:695-670, 1994
159. Blanke C, Kasimis B, Schein P, et al: A phase II trial of trimetrexate (TMTX), 5-fluorouracil (5-FU) and leucovorin (LVC) in patients with unresectable or metastatic colorectal cancer. Proc Am Soc Clin Oncol 15:198, 1996 (abstr 433)
160. Conti JA, Kemeny NE, Saltz LB, et al: Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen in advanced colorectal cancer. Cancer 75:769-774, 1995
161. O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994
162. Chang YM, Zielinski Z, Izzo J, et al: Pretreatment of human colon carcinoma cells to DI1694 (Tomudex) markedly enhances 5-fluorouracil cytotoxicity. Proc Am Assoc Cancer Res 330, 1994 (abstr 1966)
163. Aschele C, Baldo C, Guglielmi A, et al: Sequence dependent synergism between Tomudex and Irinotecan in human colon cancer cells in vitro. Ninth NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, the Netherlands, March 12-15, 1996 (abstr 302)